CardiovascularHard To Treat Diseases, Inc. (HTDS) Experiments With Hyperbaric Oxygenation (HBO) Traumatic Brain Injury
Hard to Treat Diseases, Inc. (HTDS:PK), announced that researchers in its Slavica BioChem division have reported results on experiments in which the potential beneficial effects of Hyperbaric oxygenation (HBO) after traumatic brain injury have been explored. These experiments were conducted in collaboration with doctors from the Hyperbaric Medical Center, School of Medicine, University of Belgrade, Serbia.
Hyperbaric oxygen (HBO) has been used as a primary or adjunctive therapy over the last 50 years with controversial results, both in experimental and clinical studies. However, the mechanisms underlying the neuroprotective vs. neurodegenerative effects of HBO treatment are still uncertain.
The results of the research group revealed that repetitive HBO treatments, which started 1 hour after traumatic brain injury significantly, reduced axonal loss and neuronal degeneration, suggesting that HBO was able to attenuate the effects of brain damage by reducing the progression of neuronal injury.
These data indicate that HBO-induced prevention of neurodegeneration might be beneficial in improvement of neurological outcome after traumatic brain injury.
Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer said (sic) "The experiments were performed on rats, but since we haven"t hyperbaric chambers, HBO treatments were performed at the Hyperbaric Medical Center. These data for the first time showed (all was visualized using immunohistochemical technique and specific antibodies to neuronal markers) that HBO prevent axonal loss and neuronal degeneration, since data concerning brain injury are lacking and are controversial. "
The results were presented by Professor Mirjana Stojiljkovic. (Professor Stojiljkovic is in the process of becoming HTDS Medical Advisor - Officer of the company). In a summary, Poster presentation was available for review by attendees at the 38th Annual Meeting of Society for Neuroscience"s (SfN). 15 to 19, 2008 in Washington, DC, USA. Professor Stojiljkovic reported that poster attracted numerous scientists and medical doctors, and for close to 4 hours discussion on this topic continued. Each year SfN provides the premier venue for neuroscientists to share research findings. By attending lectures, symposia, and workshops, meeting attendees experience the most exciting and cutting-edge research the field of neuroscience has to offer. SfN"s annual meeting draws diverse attendees from all over the world.
In other company news, along with the Washington poster filing the company expects to be in a position to file its Q2 financial results, and an updated Pink Sheets Adequate Disclosure with a legal opinion shortly and perhaps as early as this week. Mr.Terry Yuan HTDS CEO said " These are exciting times for us at HTDS. There are a lot of moving parts now within HTDS, which are all positive, and which may have more than better than expected results for us as a whole organization. This includes our IP claim and our Q2 financial statements which are currently being translated from Chinese to USA standards, to name a few. As a company we are pleased to acknowledge that our corporate objectives and set targets are being met.
The company will release further updates as they become available.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision"s under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc."s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc."s control. In addition to those discussed in Hard to Treat Diseases, Inc."s press releases, public filings, and statements by Hard to Treat Diseases, Inc."s management, including, but not limited to, Hard to Treat Diseases, Inc."s estimate of the sufficiency of its existing capital res, Hard to Treat Diseases, Inc."s ability to raise additional capital to fund future operations, HTDS Corporation"s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc."s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Hard to Treat Diseases